CL-82198 是MMP-13选择性抑制剂。它能够与 MMP-13 的整个 S1' 口袋结合，这是其对 MMP-13 选择性和对其他 MMP 缺乏抑制活性的基础。它可用于研究骨关节炎。

CL-82198 is a selective inhibitor of MMP-13 and it is a pharmacologic treatment for preventing osteoarthritis (OA) progression. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs.

CL-82198 decreases CTGF and TGF-β1 protein levels in hepatic stellate cells[3]. CL-82198 (10 μM; 24 hours) obviously reduces LS174 cell migration[1].

CL82198 (1-10 mg/kg; i.p.; every other day for 12 weeks) treatment avoids and decelerates MLI-induced osteoarthritis progression.

307002-71-7

C17H22N2O3

302.37

DMSO:100 mg/mL (330.72 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years